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Pulmonary physicians commonly develop relationships with lung cancer patients through the
evaluation and staging of the disease prior to the discussion of treatment options with oncol-
ogists. Given the relationship that develops, a pulmonologist is often asked about aspects of
the treatment plan that may be slightly outside of their comfort zone. The aim of this overview
of medical treatment of nonesmall cell lung cancer is to provide the pulmonologist with an
overview of the evidence guiding current practice so that they can be more comfortable
answering their patients’ questions while awaiting the expert opinion of the oncologist. We
discuss standard chemotherapeutic agents, their common side effects, and their use in the
adjuvant and neoadjuvant setting, as definitive therapy for locally advanced disease, as palli-
ative therapy for advanced disease, and as maintenance therapy. We also discuss the mecha-
nisms of action and side effects of targeted therapies (including inhibitors of vascular
endothelial growth factor [VEGF], epidermal growth factor receptor [EGFR] signaling and
the anaplastic lymphoma kinase [ALK] protein), their currently accepted uses, and upcoming
phase III trials, the results of which may influence standard practice.
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The pulmonologist plays a critical role in the evaluation and
management of lung cancer. Traditionally, this role
includes the evaluation of indeterminate lung nodules, the
diagnosis and staging of the cancer, evaluation and opti-
mization of cardiopulmonary fitness for treatment plan-
ning, the palliation of symptoms related to treatment, and
the surveillance of disease recurrence after curative intent
therapy. Contact with lung cancer patients in these roles
frequently leads to the development of close physician-
patient relationships. Lung cancer patients will often feel
comfortable with their pulmonologist, and thus may ask
questions slightly outside the pulmonologists’ main areas of
expertise. In particular, lung cancer patients may wonder
about treatment recommendations, when chemotherapies
may be suggested, and what to expect from their
treatment.
Contemporary treatment options for nonesmall cell lung
cancer (NSCLC) include surgery, radiation, traditional
chemotherapy, and targeted therapies, with the choice of
modality driven by stage of disease, histology, andpotentially molecular changes within the tumor.1 While
surgery offers the best chance for cure in patients with
localized disease, most patients are diagnosed with locally
advanced or metastatic disease1,2 or relapse after surgery
and will require some type of systemic therapy, whether it
be chemotherapy and/or targeted agents. The goal of this
review is to provide the pulmonologist with an overview of
medical therapies for lung cancer, highlighting the clinical
studies that support current practice, so it is easier to
answer patient questions while awaiting the expert advice
of the medical oncologist. In addition, this review will
describe the novel agents that are currently in late phase
development as well as the safety and toxicity of current
and emerging treatment options.Current medical treatment of NSCLC
Traditional chemotherapy
Combination chemotherapy is generally recommended for
metastatic NSCLC.1 Many chemotherapeutic agents target
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tumor cells proliferate more quickly than many other cells
within the body. Some of these agents function by causing
damage to deoxyribonucleic acid (DNA) and/or inhibiting
DNA synthesis and repair.3 Chemotherapeutic agents can be
classified into the following major categories (Fig. 1):
antimicrotubule agents, topoisomerase inhibitors, antime-
tabolites, antitumor antibiotics, and alkylating agents
(includes platinum agents).4 Although no combination has
been shown to confer a significant advantage over others in
patients with metastatic NSCLC,5 standard of care generally
includes a platinum-based (eg, cisplatin, carboplatin)
doublet regimen.1,3,6 While some studies suggest that
cisplatin- and carboplatin-based doublet therapy may have
different efficacy in the treatment of NSCLC, the topic
remains controversial. Choice of the platinum agent for
doublet therapy is often be based on differences in the
toxicity profiles of these 2 agents.7,8
Specific dosage and treatment regimens for platinum-
based doublet chemotherapy vary based on each specific
doublet combination and treatment setting (eg, adjuvant,
with radiation therapy), although the mode of administra-
tion of these agents is generally by intravenous infusion.1
No additional benefit has been demonstrated from the
addition of a third chemotherapeutic agent to doublet
regimens,9 and retrospective studies suggest that maximum
clinical benefit in patients with metastatic NSCLC occurs
with 4e6 treatment cycles.10e12
In the absence of major differences in efficacy, safety
profiles of chemotherapeutic agents influence treatment
decisions in NSCLC. Table 1 provides a summary of the most
frequent toxicities associated with the chemotherapy
agents that are often used to treat NSCLC.13e16 As these
chemotherapy agents are generally being used in combi-
nation to treat NSCLC, the risk of overlapping or additive
toxicities should be considered. Hematologic effects
remain the major safety issue with traditional chemo-
therapy for metastatic NSCLC, including both older and
newer regimens.5,17 Overall, pemetrexed appears to have
a more favorable toxicity profile when compared with otherFig. 1 Classification of traditiontraditional chemotherapy agents in direct comparative
trials,17,18 producing lower rates of hematologic toxicity
and alopecia versus other regimens.Targeted therapy
As our understanding of the molecular pathways that
contribute to lung carcinogenesis has evolved, targeted
agents that inhibit mediators of angiogenic (eg, vascular
endothelial growth factor receptor [VEGFR]) and/or
proliferative (eg, epidermal growth factor receptor [EGFR])
signaling pathways have been developed for the treatment
of NSCLC (Fig. 2).19 VEGF-A (or VEGF) is one of several
members of the VEGF family of signaling factors that
mediate proangiogenic effects through activation of
receptor tyrosine kinases (VEGFR-1, -2, and -3). VEGF
signaling is the most well-studied angiogenic pathway;
however, more recently, other signaling pathways including
platelet-derived growth factor (PDGF) and fibroblast
growth factor (FGF) have also been demonstrated to
contribute to angiogenesis through effects on cellular
proliferation and migration.20,21 Signaling mediated by the
EGFR family of receptor tyrosine kinases (4 members
include EGFR or human epidermal growth factor receptor 1
[HER1], HER2, HER3, and HER4) promotes cellular differ-
entiation, proliferation, and survival22,23; in addition, EGFR
and/or its ligands (eg, EGF) are overexpressed in many solid
tumors, including NSCLC.24 Based on this rationale, tar-
geted agents have been developed as a therapeutic
approach for the treatment of NSCLC.25,26
Two main types of agents, monoclonal antibodies that
either bind to growth factors (ligands) or to the receptor
extracellular domain to prevent activation27 and tyrosine
kinase inhibitors (TKIs) that bind to the intracellular cata-
lytic domain to inhibit receptor kinase activity,28 have been
the focus of targeted therapy in NSCLC thus far. Currently,
bevacizumab (Avastin, Genentech), a monoclonal anti-
body directed against VEGF, erlotinib (Tarceva, Gen-
entech) and gefitinib (Iressa, AstraZeneca), bothal chemotherapeutic agents.
Table 1 Common toxicities associated with chemotherapy agents for the treatment of NSCLC.
Drug class/agent Potential safety/toxicity concerns Notes
Antimetabolites16
Gemcitabine Myelosuppression (particularly neutropenia),
fever, headache, arthralgias, myalgias
Hemolytic-uremic syndrome is rare but fatal
and requires immediate discontinuation
Pemetrexed Myelosuppression, mucositis, skin rash
(usually hand-foot syndrome)
Folic acid and vitamin B12 supplementation
decreases toxicities
Platinum/alkylating agents15
Carboplatin Renal insufficiency, nausea and vomiting
(less than cisplatin), peripheral neuropathy,
auditory impairment, myelosuppression
(more than cisplatin)
Renal damage can be minimized with vigorous
hydration during therapy
Cisplatin Renal insufficiency, nausea and vomiting,
peripheral neuropathy, auditory impairment,
myelosuppression (particularly thrombocytopenia)
Renal damage can be minimized with vigorous
hydration during therapy
Antitumor antibiotics14
Etoposide Myelosuppression, nausea, vomiting, diarrhea,
mucositis, alopecia
Risk for secondary malignancies
Antimicrotubule agents
Taxanes13
Docetaxel Myelosuppression (particularly neutropenia), edema,
alopecia, nail damage, rash, diarrhea, nausea, vomiting,
asthenia, neuropathy (less than paclitaxel), skin toxicity
Premedication is necessary to avoid fluid
retention syndrome and hypersensitivity
reaction and may reduce skin toxicitya
Paclitaxel Myelosuppression (particularly neutropenia),
nausea and vomiting, alopecia, arthralgia, myalgia,
peripheral neuropathy
Premedication is necessary to avoid major
hypersensitivity reactionsb; reactions still
occur in 3% of patients who receive
effective prophylaxis
Vinca alkaloids13
Vinblastine Myelosuppression (neutropenia), constipation, alopecia,
malaise, bone pain, mucositis
Potent vesicant and may cause tissue damage
if extravasation occurs
Vinorelbine Myelosuppression (neutropenia), alopecia, diarrhea,
nausea, vomiting, asthenia, neuromyopathy
Potent vesicant and may cause tissue damage
if extravasation occurs
NSCLC, nonesmall cell lung cancer.
a The most common prophylactic regimen to prevent hypersensitivity reaction and fluid retention syndrome is dexamethasone 8 mg
orally twice daily for 3 or 5 days starting 1 or 2 days, respectively, before docetaxel, with or without H1-receptor (eg, diphenhydramine)
and H2-receptor (eg, cimetidine, famotidine, or ranitidine) antagonists given 30 min before docetaxel.
b The following regimen is recommended to prevent major hypersensitivity reactions: dexamethasone 20 mg orally or intravenously, 12
and 6 h before treatment paclitaxel; an H1-receptor antagonist 30 min before treatment; and an H2-receptor antagonist 30 min before
treatment.
476 P. Mazzone, T. Mekhailreversible EGFR TKIs, and most recently crizotinib
(Xalkori, Pfizer), a selective, adenosine-50-triphosphate
(ATP)-competitive ALK and mesenchymal epithelial transi-
tion factor (MET)/hepatocyte growth factor (HGF) TKI, are
the only targeted agents to be approved by the United
States (US) Food and Drug Administration (FDA) for NSCLC.
The indication for gefitinib was later restricted in the US for
the continued treatment of patients with locally advanced
or metastatic NSCLC who are benefiting or have benefited
from gefitinib.29 Next-generation targeted agents have
been developed and are in an advanced stage of clinical
development for the treatment of NSCLC (Fig. 2).
The mode of administration of targeted therapy depends
largely on the type; monoclonal antibodies are generally
administered intravenously, while many of the anti-
angiogenic and EGFR-targeted TKIs are available orally.30
While generally considered less toxic than chemotherapy,
targeted agents are associated with specific safety
concerns, some of which are class effects related to theirmechanism(s) of action. Although phase III safety data are
not yet available for crizotinib, vision disorder and gastro-
intestinal events have been the most common toxicities
reported in earlier stage clinical trials thus far.31,32 Table 2
provides a summary of the most frequent toxicities associ-
ated with antiangiogenic agents that are approved or in
phase III clinical development for NSCLC treatment. Most
antiangiogenic therapy-associated toxicity is of a non-
hematologic nature, although myelosuppression does occur
with some agents, such as sunitinib.33,34 Hypertension,
bleeding events, gastrointestinal perforation, proteinuria,
and infusion-site reactions are toxicities associated with
bevacizumab for which close monitoring is warranted.25 The
approved product labeling for bevacizumab highlights the
risks of gastrointestinal perforation, surgery and wound
healing complications requiring at least 28-day breaks in
therapy both before and after surgery, and potentially
severe or fatal hemorrhage as black boxed warnings.25 In
addition, because of potential safety concerns, the National
Fig. 2 Mechanism of action of targeted agents approved or in phase III clinical development for NSCLC. Akt, protein kinase B (aka
v-akt murine thymoma viral oncogene homolog); EGFR, epidermal growth factor receptor; ERK, extracellular signal-regulated
kinase; MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of rapamycin; NSCLC, nonesmall cell lung
cancer; PDGFR, platelet-derived growth factor receptor; PI3K, phosphatidylinositol-3-kinase; raf, v-raf 1 murine leukemia viral
oncogene homolog 1; Ras, retrovirus-associated DNA sequences; VEGFR, vascular endothelial growth factor receptor.
Current and emerging medical treatments 477Comprehensive Cancer Network (NCCN) recommends that
any regimen with high risk for thrombocytopenia be used
with caution when combined with bevacizumab.1
Table 3 provides a summary of the most frequent toxic-
ities associated with EGFR inhibitors that are approved or in
phase III clinical development for NSCLC treatment. Overall,
rash has emerged as a common adverse event with agents
that target EGFR, including both monoclonal antibodies and
TKIs.35 Skin toxicity can be severe in some cases,36,37 with
the product labeling for erlotinib warning of the risk of
potentially fatal bullous, blistering, and exfoliative condi-
tions.26 Gastrointestinal complaints, including diarrhea, are
among themost common adverse events with EGFR-directedtherapies.37 Interstitial lung disease, albeit infrequent with
use of the approved EGFR TKIs erlotinib and gefitinib,38,39 is
a toxicity that warrants vigilance in clinical practice.26,29
Key topics in the medical treatment of NSCLC
Chemotherapy in the neoadjuvant and adjuvant
settings
Patient scenario
The pulmonologist is asked to evaluate a 57-year-old
former smoker for a 2.5 cm spiculated right upper lobe
Table 2 Common toxicities associated with approved and investigational antiangiogenic agents for the treatment of NSCLC.
Agent Potential safety/toxicity concerns
Aflibercept131 Fatigue, nausea, vomiting, dysphonia, hypertension, proteinuria
ASA404134 Neutropenia, anemia, dyspnea, leukopenia
Bevacizumab82,83 Myelosuppression, febrile neutropenia, hypertension, hemorrhage
(particularly pulmonary hemorrhage), proteinuria
BIBF 1120148 Reversible ALT elevation, diarrhea, nausea
Cediranib149,150 Hypertension, gastrointestinal toxicity, neutropenia, febrile neutropenia,
thrombocytopenia, anemia, fatigue, dyspnea, hand-foot syndromea
Motesanib151 Fatigue, diarrhea, hypertension, nausea, vomiting, dehydration, anorexia,
dyspnea, anemia, abdominal pain, neutropenia, gallbladder toxicity, thrombosis
Pazopanib152,153 Fatigue, diarrhea, hypertension, hair color changes, nausea, anorexia, vomiting,
alanine aminotransferase increase
Sorafenib129 Thrombocytopenia, dermatologic events (rash, hand-foot skin reaction, pruritus),
diarrhea, hypertension, hemorrhage
Sunitinib154,155 Fatigue, myalgia, dyspnea, nausea and vomiting, stomatitis, diarrhea, hypertension,
lymphopenia, erythema
Vandetanib156e159 Diarrhea, rash, myelosuppression, hypertension
ALT, alanine aminotransferase; NSCLC, nonesmall cell lung cancer.
a Note that cediranib-associated toxicities reported during phase II study reflect patients receiving a higher dose (30 mg) than is
currently being studied (20 mg).
478 P. Mazzone, T. Mekhaillung nodule. The patient is otherwise fit and active
without significant comorbidities. A bronchoscopy
reveals adenocarcinoma within the lung nodule. Posi-
tron emission tomography (PET) imaging suggests N1
node involvement without other evidence of spread.
Brain imaging is normal, as are pulmonary function
studies. The pulmonologist discusses the results of the
biopsy with the patient, explaining that surgical
resection with curative intent, including sampling of
the mediastinal nodes, is recommended. The patient
asks if he or she will need chemotherapy before or after
the surgery.Table 3 Common toxicities associated with approved and inves
Agent Potential safety/toxicit
Afatinib (BIBW 2992)146,160 Diarrhea, rash/acne
Cetuximab98 Acne-like skin rash, dia
Erlotinib101 Rash, diarrhea, anorex
Gefitinib100 Rash, dry skin, diarrhea
PF00299804161e164 Rash, dermatitis acneifThe evidence
Neoadjuvant therapy
Phase III clinical studies from the early 1990s suggested
a role for neoadjuvant (pre/perioperative) chemotherapy
for NSCLC.40,41 However, a more recent phase III study
(S9909) failed to show that preoperative chemotherapy
with paclitaxel/carboplatin plus surgery for stage IB to IIIA
NSCLC is statistically better than surgery alone with respect
to overall survival (OS; median, 62 vs 41 months; hazard
ratio [HR], 0.79; 95% confidence interval [CI], 0.60e1.06;
P Z 0.11) or progression-free survival (PFS; median, 33 vs
20 months; HR, 0.80; 95% CI, 0.61e1.04; P Z 0.10).42tigational EGFR inhibitors for the treatment of NSCLC.
y concerns
rrhea, infusion-related reactions
ia, stomatitis, ocular toxic effect, infection
orm, acne, anorexia, diarrhea, fatigue, stomatitis, mucositis
Current and emerging medical treatments 479Premature trial closure attributed to the favorable results
of adjuvant treatment trials (discussed below) may have
contributed to the lack of statistical significance. The S9909
investigators themselves noted that a stronger body of
evidence exists for postoperative chemotherapy for early-
stage NSCLC.42 A recently published meta-analysis
capturing 32 randomized clinical trials showed no differ-
ences in overall or disease-free survival between post-
operative versus preoperative chemotherapy in patients
with resectable lung cancer.43
Adjuvant therapy
Available clinical trial results collectively support the
ability of cisplatin-based chemotherapy, administered after
curative intent surgery, to prolong OS versus observation
alone (Table 4).44e47 Long-term follow-up from some of
these key adjuvant trials has produced mixed results.48,49
There were significant differences reported for the
benefit of adjuvant chemotherapy in OS in the International
Adjuvant Lung Cancer Trial (IALT) trial between those who
had <5 years of follow-up (HR, 0.86; 95% CI, 0.76e0.97;
PZ 0.01) versus those who had >5 years of follow-up (HR,
1.45; 95% CI, 1.02e2.07; P Z 0.04; p-value for
interaction Z 0.006).49 The American College of Chest
Physicians (ACCP) recommends routine adjuvant chemo-
therapy for completely resected stage II to III (including
incidental IIIA N2) disease, but not stage I disease.50,51
The role of adjuvant chemotherapy in stage IB disease
remains more controversial. Neither the LACE meta-anal-
ysis47 nor any of the recently published large randomized
controlled trials (National Cancer Institute of Canada Clinical
Trials Group [JBR-10], Adjuvant Navelbine International
Trialist Association [ANITA], IALT, or Adjuvant Lung Project
Italy [ALPI])44e46,49,52 have shown a significant OS benefit for
cisplatin therapy in stage IB subgroups overall. Furthermore,
the Cancer and Leukemia Group B (CALGB) 9633 trial, which
was composed entirely of stage IB patients, has not reported
a significant OS advantage for paclitaxel/carboplatin adju-
vant therapy (HR, 0.83; 90% CI, 0.64e1.08; P Z 0.12).53
However, the possible benefit of adjuvant chemotherapy
for larger stage IB tumors (ie, tumors >4 cm) has been sug-
gested from subgroup analyses fromboth the CALGB and JBR-
10 trials.46,53 The CALGB 9633 trial reported significant OS
(median, 99 vs 77 months; HR, 0.69; 90% CI, 0.48e0.99;
P Z 0.042) and disease-free survival (median, 96 vs 63
months; HR, 0.69, 90% CI, 0.49e0.97; PZ 0.035) advantages
in an unplanned subset analysis of patients with tumors
4 cm.53 In the JBR-10 trial of adjuvant cisplatin/vinorelbine
versus observation, no survival benefit was reported for
patients with stage IB tumors overall; among patients with
stage 1B disease, tumor size was predictive of chemotherapy
effect (interaction P Z 0.02 for tumor size 4 cm). For
patients with tumors4 cm, the 5-year survival rate was 59%
in the observation group versus 79% with chemotherapy.48
The NCCN therefore, recommends cisplatin-based chemo-
therapy as adjuvant therapy for patients with stage IB NSCLC
with tumors >4 cm, and for those with stage II and stage IIIA
disease.1
Options for adjuvant treatment in NSCLC include the
commonly used regimens in the key clinical trials
mentioned above (cisplatin/vinorelbine, cisplatin/vinblas-
tine, cisplatin/etoposide)44e49 and cisplatin combined withgemcitabine,54 docetaxel,55 or pemetrexed (for patients
with nonsquamous histology).17 Cisplatin may be
substituted with carboplatin for patients with comorbidities
or those who cannot tolerate cisplatin.1,53
The role of molecular markers in choosing patients who
will benefit from adjuvant therapy and in selecting the
agents most likely to be effective is being explored.56e58
Response to the patient
Based on the evidence described above, the pulmonologist
may comfortably tell the patient that if no mediastinal
lymph nodes (N2 disease) are discovered at the time of
mediastinoscopy, there will be no role for chemotherapy
prior to lung surgery. Treatment with chemotherapy will
be discussed with her/him shortly after recovering from
surgery. If her/his cancer is found to have advanced
beyond the lung nodule and she/he is feeling well after
surgery, a platinum-based doublet chemotherapy regimen
will be offered with the intent of improving her/his
survival.Chemo/radiotherapy as definitive treatment for
stage IIIA/IIIB disease
Patient scenario
A 65-year-old smoker is seen for evaluation of a productive
cough. He describes a couple of weeks of hoarseness as
well. A chest x-ray shows a left upper lobe mass. A chest
computed axial tomography (CAT) scan confirms the pres-
ence of a spiculated left upper lobe mass with left hilar,
aortopulmonary (AP) window, and subcarinal adenopathy.
Endobronchial ultrasound (EBUS)-guided bronchoscopy is
performed, confirming the presence of squamous cell
carcinoma in the N2 nodes as well as the mass. The patient
has mild chronic obstructive pulmonary disease (COPD) and
is able to be reasonably active. He asks if he will need
chemotherapy.
The evidence
Patients with stage IIIA NSCLC represent a heterogeneous
population with respect to lymph node involvement and
associated resectability, warranting an intricate multidis-
ciplinary collaboration to determine the most appropriate
treatment for a given patient.50 The majority of stage IIIA
patients will have N2 lymph node involvement identified
prior to surgery. The following evidence pertains to this
group rather than the group with incidentally discovered N2
disease found in the nodes removed at the time of
a resection for clinical stage I or II disease. Patients in the
latter group should be treated according to the recom-
mendations for adjuvant treatment given above; for these
patients, in addition to chemotherapy, adjuvant radiation is
also usually recommended based on the results of an
analysis of stage II or III NSCLC patients entered into the
Surveillance, Epidemiology, and End Results (SEER) data-
base who were treated postoperatively with adjuvant
radiotherapy or observation. This analysis demonstrated
a significant survival benefit with postoperative radio-
therapy for patients with N2 nodal disease discovered at
the time of surgery (HR, 0.855; 95% CI, 0.762e0.959;
P Z 0.0077), but not in patients with N1 or N0 disease.59
Table 4 Clinical trials and Meta-analyses of adjuvant Cisplatin-based chemotherapy for NSCLC.
Trial or meta-analysis Distribution
by stage
N Regimen Efficacy and safety
International Adjuvant Lung
Cancer Trial (IALT)44
I (36.5%)
II (24.2%)
III (39.3%)
1867 Cisplatin combined with
etoposide (56.5%), vinorelbine
(26.8%), vinblastine (11.0%), or
vindesine (5.8%) vs observation
OS, 44.5% vs 40.4% at 5 years
(HR, 0.86; 95% CI, 0.76e0.98;
P < 0.03); PFS, 39.4% vs 34.3%
at 5 years (HR, 0.83; 95% CI,
0.74e0.94; P < 0.003)
AEs: 22.6% had 1 grade 4 AE
(most common were
neutropenia,
thrombocytopenia, and
vomiting); 7 (0.8%) deaths due
to chemotherapy-induced
toxicity
National Cancer Institute of
Canada Clinical Trials Group
JBR-1046
IB (45%)
II (55%)
482 Cisplatin plus vinorelbine vs
observation
OS, 94 vs 73 months (HR, 0.69;
P Z 0.04); PFS, not reached vs
46.7 months (HR, 0.60;
P < 0.001); 5-year survival, 69%
vs 54% (P Z 0.03)
AEs: neutropenia (88%), fatigue
(81%), nausea (80%), anorexia
(55%), vomiting (48%),
neuropathy (48%), constipation
(47%); 2 (0.8%) deaths from
chemotherapy-related toxicity
Adjuvant Navelbine
International Trialist
Association (ANITA)45
IB (36%)
II (24%)
IIIA (39%)
840 Cisplatin plus vinorelbine vs
observation
Median survival, 65.7 vs 43.7
months (95% CI, 47.9e88.5
months); HR adjusted risk for
death, (95% CI, 0.66e0.96;
P Z 0.017)
AEs: neutropenia (92%), anemia
(78%), thrombocytopenia
(14%), febrile neutropenia
(9%); 7 (2%) deaths due to
chemotherapy-associated
toxicity
Lung Adjuvant Cisplatin
Evaluation (LACE)47
(meta-analysis)
IAeIII 4584 Trials analyzed evaluated
cisplatin plus vinorelbine,
etoposide, vindesine,
mitomycin, or vinblastine
Overall benefit from
chemotherapy (HR, 0.89; 95%
CI, 0.82e0.96; P Z 0.005)
Rate of overall grade 3/4
toxicity among trials, 66%;
most frequent toxicity was
neutropenia (grade 3, 9%;
grade 4, 28%)
AE, adverse event; CI, confidence interval; HR, hazard ratio; NSCLC, nonesmall cell lung cancer; OS, overall survival; PFS, progression-
free survival.
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a component of concurrent chemoradiation for potentially
curative, definitive treatment of stage IIIA N2 disease.1,50
The use of definitive chemoradiation as standard therapy
of stage IIIA disease is supported by a lack of convincing
long-term benefit for surgery in this subset and the
improved results of the combination over radiation
alone.60,61 For example, in the Intergroup 0139/R9309 trial,
which evaluated concurrent chemotherapy plus radio-
therapy followed by surgery (n Z 202) versus chemo-
therapy with definitive radiotherapy without surgery
(n Z 194) in patients with stage IIIA N2 disease,60 OS wassimilar between the 2 groups (median, 23.6 with surgery vs
22.2 months without surgery; HR, 0.87; 95% CI, 0.70e1.10;
P Z 0.24). However, in an exploratory analysis, OS was
improved for patients who underwent lobectomy (median,
33.6 vs 21.7 months; P Z 0.002), but not pneumonectomy
(median, 18.9 vs 29.4 months; P Z not significant) versus
chemotherapy plus radiotherapy alone. Among patients
included in this study, the main beneficiaries of surgery
were those in whom the mediastinum was downstaged to
N0 with preoperative treatment. The results of this trial
also suggest against surgery for patients with bulky medi-
astinal disease.
Current and emerging medical treatments 481Results of the 7-year follow-up analysis of the CALGB
8433 study conducted in stage III NSCLC patients showed
that treatment with cisplatin and vinblastine chemotherapy
prior to radiation therapy resulted in increased median OS
compared with radiation therapy alone (13.74 vs 9.56
months; PZ 0.012).62 Similarly, in a phase III study of stage
II, IIIA, and IIIB NSCLC patients, the median survival for
patients receiving chemotherapy plus radiation was 13.2
months compared with 11.4 months with standard radiation
and 12 months with twice-daily radiation (P Z 0.04).63 In
another phase III study, concurrent treatment with
chemotherapy (cisplatin, vindesine, and mitomycin) and
radiation generated an increased response rate (RR; 84.0%
vs 66.0%; P Z 0.0002) and improved median survival (16.5
months vs 13.3 months; PZ 0.03998) in unresectable stage
III NSCLC patients compared with sequential treatment.64
In the Radiation Therapy Oncology Group (RTOG) 9410
phase III trial, the survival benefit of concurrent treatment
compared with sequential chemotherapy and radiation was
demonstrated in a study using cisplatin and vinblastine as
the chemotherapeutic agents.65
Cisplatin/etoposide and cisplatin/vinblastine represent
NCCN-recommended chemotherapy regimens for use with
definitive concurrent chemoradiation, with cisplatin
preferred over carboplatin given the insufficient clinical
trial evaluation of the latter agent in this setting.1 The
optimal chemotherapy to combine with radiation therapy
remains controversial. Some chemotherapeutic agents
commonly combined with either cisplatin or carboplatin
include docetaxel, paclitaxel, and pemetrexed (in non-
squamous histology). The incorporation of targeted therapy
into the mix remains investigational.
Concurrent chemoradiation is likewise recommended for
patients with stage IIIB (both T1-3, N3 and T4, N2-3) disease,
for whom surgery is not a viable option in the majority of
cases.1,66 According to the ACCP, the target stage IIIB pop-
ulation for platinum-based chemoradiation includes
patients with a good performance status and minimal (5%)
weight loss, with use in patients with less favorable char-
acteristics based on careful consideration.66 The use of
consolidation chemotherapy after chemoradiation for stage
IIIB disease is an area lacking uniform consensus.1 There has
been a clinical practice trend toward using chemoradiation
alone67 given the high toxicity but lack of OS benefit for
consolidation docetaxel versus observation in the Hoosier
Oncology Group/US Oncology trial.68
Response to the patient
Chemotherapy should be a part of treatment. This will
usually involve a platinum-based doublet in addition to
radiation therapy administered concurrently. Surgery is not
likely to be of benefit, although it may be discussed in
certain circumstances. It is important to remind the patient
that the goal of concurrent chemoradiation therapy for
stage IIIA disease is cure.Chemotherapy for advanced (stage IIIB/IV) disease
Patient scenario
A 73-year-old former smoker is seen for evaluation of
a cough and chest pain. Chest imaging reveals a mass in theright lower lobe abutting the pleura with an adjacent small
right pleural effusion. There are liver lesions and an adrenal
mass. Biopsy of the adrenal mass confirms adenocarcinoma
of lung origin. The patient is otherwise reasonably active
and has not lost any weight. He is quite distraught and asks
if there is more benefit to chemotherapy than potential
harm. He also asks if chemotherapy choices will be based
on his type of cancer and wonders if any of the new
treatments he has been hearing about will be appropriate
for him.
The evidence
Traditional chemotherapy
Patients with advanced NSCLC, either chemoradiation-
ineligible stage IIIB disease or stage IV disease with a good
performance status (generally EasternCooperativeOncology
Group [ECOG] 0 or 1), have the potential to benefit from
chemotherapy, which may be given as a platinum-based
doublet whenever feasible.1,69e71 Platinum-based chemo-
therapy prolongs survival and improves symptoms and
quality of life compared with best supportive care (BSC)
alone.1,69e72 Platinum-based chemotherapy has produced 1-
year survival rates of 30%e40%, with effective combinations
including carboplatin/paclitaxel, cisplatin/paclitaxel,
cisplatin/vinorelbine, cisplatin/gemcitabine, cisplatin/
docetaxel, carboplatin/gemcitabine, carboplatin/doce-
taxel, and cisplatin/pemetrexed (for nonsquamous
histology) (Table 5).5,17,54,55,73e77 While platinum-based
doublets generally produce similar RRs and survival dura-
tions among regimens,5,75 they differ somewhat in terms of
toxicity, convenience, and cost, and thus the choice of
therapy should be individualized for each patient.1 Chemo-
therapy is recommended for a defined course of 4e6
cycles,1,69 as studies with traditional agents have shown no
survival benefit and diminished quality of life with extended
therapy.5,10e12,78,79 This concept has recently been chal-
lenged by the results of an Australian meta-analysis of 13
randomized controlled trials (NZ 3027), which showed that
extending chemotherapy beyond a standard number of
cycles significantly improved PFS (HR, 0.75; 95% CI,
0.69e0.81; P< 0.00001) andOS (HR, 0.92; 95%CI, 0.86e0.99;
P Z 0.03), but at the expense of more frequent adverse
events and possible negative effects on quality of life.80
The recent inclusionof pemetrexedwithin chemotherapy-
based doublet regimens has provided the first evidence of
differences in patient outcomes based on NSCLC histology.17
In a large phase III trial of first-line advanced NSCLC therapy
(N Z 1725),17 pemetrexed/cisplatin was non-inferior to
gemcitabine/cisplatin regarding the primary endpoint of OS;
however, it was significantly more effective in prolonging OS
in patients with adenocarcinoma (median, 12.6 vs 10.9
months with gemcitabine/cisplatin; P Z 0.03) or large-cell
carcinoma (median 10.4 vs 6.7 months; P Z 0.03).
Conversely, among patients with squamous cell carcinoma,
gemcitabine/cisplatin conferred a significant OS benefit
(median, 10.8 vs 9.4 months with pemetrexed/cisplatin;
P Z 0.05). On the basis of these histology-specific findings,
pemetrexed is neither approved nor recommended for use in
patients with tumors of squamous cell histology. Another
more recent combination of nanoparticle albumin-bound
(nab) paclitaxel combined with carboplatin demonstrated
a higher RR than paclitaxel and carboplatin in a histologic
Table 5 Phase III trials of traditional chemotherapy for patients with advanced NSCLC.
Trial Stage N Regimen Efficacy
FACS Cooperative Group54 IIIB/IV 602 Cisplatin/irinotecan (IP) vs
carboplatin/paclitaxel (TC) vs
cisplatin/gemcitabine (GP) vs
cisplatin/vinorelbine (NP)
No significant differences in RR
or OS between the study arms
TAX 34655 IIIB/IV 1218 Docetaxel/cisplatin (DC) or
docetaxel/carboplatin (DCb) vs
vinorelbine/cisplatin (VC)
RR significantly higher with DC
vs VC (31.6% vs 24.5%;
P Z 0.029); no significant
difference in RR between DCb
vs VC; no differences in OS
between the study arms
Cisplatin/Pemetrexed vs
Cisplatin/Gemcitabine17
IIIB/IV 1725 Cisplatin/pemetrexed (PP),
cisplatin/gemcitabine (GP)
No significant differences in
RR, PFS, or OS between the
study arms
British Thoracic Oncology
Group73
III/IV 433 Docetaxel/carboplatin (DCb) vs
mitomycin/ifosfamide/
cisplatin or mitomycin/
vinblastine/cisplatin (MIC/
MVP)
RR and survival rates were
similar between the study arms
Gemcitabine/Carboplatin
Trial74
III/IV 372 Gemcitabine/carboplatin (GC)
vs mitomycin/ifosfamide/
cisplatin or mitomycin/
vinblastine/cisplatin (MIC/
MVP)
Survival rates were similar
between the study arms
Southwest Oncology Group75 IIIB/IV 202 Vinorelbine/cisplatin (VC),
paclitaxel/carboplatin (PC)
RR and OS were similar
between the study arms
ECOG Comparison of 4
Chemotherapy Regimens5
IIIB/IV 1207 Cisplatin/paclitaxel (CP),
cisplatin/gemcitabine (CG),
cisplatin/docetaxel (CD),
carboplatin/paclitaxel (CbP)
No significant differences in RR
or survival between treatment
groups; CG had significantly
longer TTP
EORTC 0897576 IIIB/IV 480 Cisplatin/paclitaxel (CP),
cisplatin/gemcitabine (CG),
paclitaxel/gemcitabine (PG)
RR and OS were similar
between the study arms
AE, adverse event; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; EORTC, European Organisation for Research and
Treatment of Cancer; FACS, Fellow, American College of Surgeons; HR, hazard ratio; NSCLC, nonesmall cell lung cancer; OS, overall
survival; PFS, progression-free survival; RR, response rate; TTP, time to progression.
482 P. Mazzone, T. Mekhailanalysis of 449 patients with squamous cell carcinoma (41% vs
24%, respectively; P < 0.001).81
Targeted therapy
While platinum-based doublet chemotherapy is regarded as
the cornerstone of first-line treatment for advanced
NSCLC,1,69 the addition of targeted agents may be benefi-
cial in specific situations. Current targeted therapy for the
treatment of NSCLC is limited to inhibition of VEGF and
EGFR signaling and an aberrant ALK protein.
VEGF inhibitors
Bevacizumabwasapproved in 2006 by theUSFDA for thefirst-
line treatment of patients with unresectable, locally
advanced, recurrent, or metastatic nonsquamous NSCLC in
combination with carboplatin and paclitaxel. Two phase III
trials of bevacizumab plus platinum-based chemotherapy
(E4599 [paclitaxel/carboplatin] and AVAiL [gemcitabine/
cisplatin]) have demonstrated benefit in prolonging PFS in
patients with advanced nonsquamous NSCLC, with an addi-
tional OS benefit in E4599 (12.3 vs 10.3 months; HR, 0.79; 95%
CI, 0.67e0.92; P Z 0.003) but not in AVAiL (median OS wassimilar and exceeded 13 months in all arms; HR, 0.93; 95% CI,
0.78e1.11; PZ 0.420 for 7.5 mg/kg bevacizumab vs placebo
and HR, 1.03; 95% CI, 0.86e1.23; P Z 0.761 for 15 mg/kg
bevacizumab vs placebo).82,83 Patients must meet specific
criteria to receive treatment with bevacizumab and chemo-
therapy, including nonsquamous histology and no history of
hemoptysis.1,69e72 Additional patient characteristics for
guiding the decision to use bevacizumab as a component of
first-line chemotherapy, which were required for participa-
tion in E4599, include performance status of 0 or 1 and no
therapeutic anticoagulation, brain metastases, significant
cardiovascular disease, or uncontrolled hypertension.1,69,71
Recent clinical trials confirmed the safety of bevacizumab
in patients with treated brain metastases84e86 and on stable
doses of anticoagulation.87
EGFR inhibitors
EGFR-targeted agents whose impact has been reported in
large phase III trials include erlotinib and gefitinib, both
reversible EGFR TKIs. Another agent, cetuximab (Erbitux,
ImClone Systems Incorporated), is a monoclonal antibody
that targets the extracellular domain of the EGFR. These
Current and emerging medical treatments 483agents have been studied as first-line therapies, as well as
in the second-line and third-line settings.
First-line therapy: First-line EGFR TKI therapy has
demonstrated activity for patients with a heightened
propensity for response, with patient selection guided by
either molecular profiling or clinical characteristics (never
smokers, female, adenocarcinoma histology, Asian descent)
that tend to be associated with tumors harboring a sensi-
tizing mutation in exons 18, 19, or 21 of the tyrosine kinase
domain of the EGFR.1,88e92 In the recently published phase
III IPASS study of gefitinib versus paclitaxel/carboplatin in
never or light former smokers with pulmonary adenocarci-
noma, gefitinib significantly prolonged PFS in the overall
study population (HR, 0.74; 95% CI, 0.65e0.85; P < 0.001).
Gefitinib also prolonged PFS in the subset of patients with
EGFR mutation-positive disease (HR, 0.48; 95% CI,
0.36e0.64; P < 0.001), while having an adverse impact in
the EGFR mutation-negative subset (HR, 2.85; 95% CI,
2.05e3.98; P < 0.001).91 Mature OS data from this study
showed no difference between gefitinib and paclitaxel/
cisplatin in the overall population (HR, 0.90; 95% CI,
0.79e1.02; P Z 0.109). There was no difference between
treatments in the EGFR mutation-positive subgroup
(HR, 1.00; 95% CI, 0.76e1.33; P Z 0.990) or the EGFR
mutation-negative subgroup (HR, 1.18; 95% CI, 0.86e1.63;
P Z 0.309).93 The lack of survival advantage of gefitinib in
patients with sensitizing mutations could be explained by
the crossover that was allowed in this study. The significant
prolongation of PFS seen in this study demonstrated the
importance of utilizing molecular predictors rather than
clinical characteristics for choosing patients who are most
appropriate for upfront use of TKIs. Erlotinib is recom-
mended as first-line therapy in patients with EGFR muta-
tions per the NCCN and gefitinib is appropriate therapy in
that context per the latest American Society of Clinical
Oncology (ASCO) clinical practice guidelines.1,69 In the
front line setting, the addition of EGFR TKIs to chemo-
therapy in unselected patients failed to improve survival in
four large randomized phase III trials.94e97
The large phase III randomized FLEX trial was conducted
in patients with EGFR-expressing (by immunohistochem-
istry) advanced disease98; a significant OS benefit was
achieved when adding cetuximab to vinorelbine/cisplatin,
with a median of 11.3 months versus 10.1 months for
chemotherapy alone (HR, 0.871; 95% CI, 0.762e0.996;
P Z 0.044). However, another study (BMS099) failed to
demonstrate a survival advantage with chemotherapy
(paclitaxel or docetaxel plus carboplatin) combined with
cetuximab compared with chemotherapy alone (median
9.69 vs 8.38 months, respectively; HR, 0.890; 95% CI,
0.754e1.051; P Z 0.169) as first-line treatment in unse-
lected patients with advanced NSCLC.99 While not approved
by the US FDA for NSCLC, the NCCN and ASCO clinical
practice guidelines include cetuximab in combination with
vinorelbine/cisplatin as a first-line option.1,69
Second-/third-line therapy: In a phase III trial in the
second-line and third-line treatment of unselected
advanced NSCLC,100 gefitinib did not produce an OS benefit
over placebo (median 5.6 vs 5.1 months; HR, 0.89; 95% CI,
0.77e1.02; PZ 0.087), and thus is only indicated in the US
for continued treatment of patients benefiting from
therapy.29 Based on results from the placebo-controlledphase III BR21 trial,101 in which erlotinib was associated
with significant improvements in the objective RR (8.9% vs
<1%; P < 0.001), PFS (median, 2.2 vs 1.8 months; HR, 0.61;
95% CI, 0.51e0.74; P < 0.001), and OS (median, 6.7 vs 4.7
months; HR, 0.70; 95% CI, 0.58e0.85; P < 0.001), erlotinib
was approved by the US FDA for locally advanced or
metastatic NSCLC that has progressed after 1 line of
chemotherapy.26 A phase III clinical trial (INTEREST)
demonstrated the non-inferiority of gefitinib versus doce-
taxel with respect to OS (median 7.6 vs 8.0 months; HR,
1.020; 96% CI, 0.905e1.150) in platinum-pretreated
advanced NSCLC.102 In summary, both erlotinib and gefiti-
nib are regarded as second-line options for advanced
NSCLC. EGFR TKI therapy has additional applicability in the
third-line setting, with erlotinib recommended for patients
with EGFR TKI-naive disease.1,69
Primary resistance to available EGFR TKIs is an important
consideration, and even patients who initially respond
eventually relapse.103 Mechanisms of both de novo and
acquired resistance to EGFR TKIs have been identified;
these include changes in EGFR (eg, the T790M EGFR muta-
tion) or in compensatory signaling through downstream
mediators (eg, Kirsten rat sarcoma viral oncogene homolog
[KRAS]), other RTKs (eg, other EGFR family members,
insulin-like growth factor receptor 1 [IGF-1R], MET), or
the echinoderm microtubule-associated protein-like
4/analplastic lymphoma kinase (EML4-ALK) fusion
protein.88,104e106 The development of agents that bind
irreversibly to EGFR, target downstream mediators of EGFR
signaling, target multiple EGFR family members, and/or
simultaneously inhibit EGFR and other tumorigenic path-
ways represent new strategies for potentially overcoming
such resistance.
ALK/MET inhibitors
The EML4-ALK fusion oncogene has been identified in
a small proportion of tumors (approximately 4%) in the
NSCLC population and is generally found in individuals who
do not typically respond to EGFR TKI therapy.107,108 EGFR
and EML4-ALK mutations are believed to be mutually
exclusive, although there are rare individual reports of
patients harboring both mutations. Crizotinib, a selective,
ATP-competitive ALK and MET/HGF TKI, was approved in
August 2011 by the US FDA for the treatment of patients
with locally advanced or metastatic NSCLC that is ALK-
positive as detected by a US FDA-approved test. Approval
of crizotinib was based on the results of Study 1001, a Part 2
expansion cohort of a phase I study,31 and PROFILE 1005,
a phase II study.32 Phase III trials of first-line crizotinib
versus chemotherapy (NCT01154140) as well as second-line
crizotinib monotherapy (NCT00932893) for patients with
ALK-positive tumors are ongoing.
Response to the patient
The pulmonologist’s knowledge of the evidence allows her/
him to tell the patient that as long as he remains otherwise
healthy, 4 to 6 cycles of traditional chemotherapy can
improve his survival and quality of life when compared with
no therapy. The type of lung cancer will influence the
choice of chemotherapy agent the oncologist recommends.
A newer treatment, bevacizumab, may be added to stan-
dard treatment, and other targeted therapy would be
484 P. Mazzone, T. Mekhailconsidered based on molecular changes within his tumor
(however, it is unlikely that this patient would have EGFR or
EML4/ALK mutations and respond to erlotinib, gefitinib, or
crizotinib, given his clinical profile).
Maintenance therapy for patients with advanced
NSCLC
Patient scenario
The patient described above then asks if he responds well
to chemotherapy, will he continue to receive it.
The evidence
Patients with responsive or stable disease after first-line
therapy may consider continuation maintenance therapy with
1 of the agents given first line (eg, bevacizumab83 or cetux-
imab98); both agents are designated as preferred per the NCCN
given that therapy in theabove trialswas continuedbeyond the
4 cycles of traditional chemotherapy until progression
occurred.109 Patients may also consider starting a different
agent not included as part of the first-line regimen (switch
maintenance therapy), such as pemetrexed,109 erlotinib,110 or
docetaxel, based on the following trials.1,111 In the placebo-
controlled phase III SATURN trial, treatment with erlotinib
after 4 cycles of platinum-based chemotherapy significantly
improved both PFS and OS, with a 29% reduction in the risk of
progressionordeath (median, 12.3 vs11.1weeks;HR, 0.71; 95%
CI, 0.62e0.82; P < 0.0001) and a 19% reduction in the risk of
death (median, 12.0 vs 11.0 months; HR, 0.81; 95% CI,
0.70e0.95;PZ0.0088).110 Similarly,maintenancepemetrexed
after 4 cycles of platinum-based chemotherapy demonstrated
significantly longer PFS (median, 4.3 vs 2.6 months with
placebo; HR, 0.50; 95% CI, 0.42e0.61; P < 0.0001) and OS
(median, 13.4 vs 10.6 months with placebo; HR, 0.79; 95% CI,
0.65e0.95; P Z 0.012) in patients with advanced NSCLC.109
FDA-approved indications for use as maintenance therapy
have been granted for pemetrexed and erlotinib. The efficacy
of docetaxel administered immediately upon completion of
gemcitabine-carboplatin first-line treatment was compared
with delayed administration and showed a significantly
increased PFS (5.7 vs 2.7months; PZ 0.0001). Median OS (12.3
vs 9.7 months; PZ 0.0853) was greater for immediate doce-
taxel, but not significantly different from delayed administra-
tion. Neither quality of life measures (P Z 0.76) nor the
incidence of adverse events differed for the 2 groups.111
Response to the patient
The pulmonologist is comfortable telling the patient that if
his cancer has responded or stabilized and he continues to
feel well, he may be offered ongoing treatment as long as
the cancer continues to respond.
Novel agents in phase III development for NSCLC
Key efficacy data for the targeted agents undergoing phase
III clinical evaluation for the treatment of NSCLC, either as
monotherapy or in combination with chemotherapy, are
summarized herein, with additional ongoing phase III trials
for which results are not yet available (including those for
therapeutic cancer vaccines) summarized in Table 6.
Except for the monoclonal antibodies bevacizumab andcetuximab, previously completed phase III clinical trials of
supplementing standard first-line chemotherapy regimens
for advanced NSCLC with a targeted agent (including the
EGFR TKIs gefitinib94,95 and erlotinib,96,97 protein kinase C
inhibitor aprinocarsen [ISIS 3521],112,113 matrix metal-
loproteinase inhibitors prinomastat [AG3340]114 and BMS-
275291,115 farnesyltransferase inhibitor lonafarnib,116
multitargeted TKI sorafenib,117,118 and vascular-disrupting
agent ASA404119) have proved unsuccessful in prolonging
survival in unselected populations. This has led to alter-
native approaches to the clinical development of targeted
therapy for advanced NSCLC, as illustrated by the ongoing
clinical trials of the various agents.Antiangiogenic agents
Small molecule TKIs
Several multitargeted antiangiogenic TKIs have been devel-
oped that targetVEGF signaling aswell as other proangiogenic
pathways, such as PDGF and FGF signaling. One of these, BIBF
1120 (Boehringer Ingelheim), inhibits VEGFR-1, -2, and -3,
PDGF receptor (PDGFR)-a/b, and FGF receptors (FGFRs)
1e3.120,121 Phase III trials evaluating the addition of BIBF 1120
or placebo to docetaxel (LUME-Lung 1, NCT00805194) or
pemetrexed (LUME-Lung 2, NCT00806819; nonsquamous
histology only) as second-line therapy in patients with NSCLC
are currently active, but no longer recruiting. Another mul-
titargeted antiangiogenic TKI, cediranib (Recentin, Astra-
Zeneca), inhibitsVEGFR-1and -2, stemcell factor receptor (c-
kit), and PDGFR-b,122 with additional activity against fms-like
tyrosine kinase 4 (FLT-4) and b/c-raf. A phase III trial designed
to evaluate cediranib 20 mg plus paclitaxel/carboplatin as
first-line therapy in advanced NSCLC (BR29; NCT00795340)
was initiated but has recently been reported as closed.123
Motesanib (AMG 706, Amgen), an inhibitor of VEGFR-1, -2,
and -3, PDGFR, c-kit, and rearranged during transfection
(RET),124 is being evaluated in an ongoing phase III study in
combination with chemotherapy for patients with advanced
nonsquamous NSCLC (MONET1; NCT00460317). Recently pre-
senteddata showednoOSbenefitwith thecombinationversus
chemotherapy alone (HR, 0.897; 95% CI, 0.776e1.035;
P Z 0.137).125 Pazopanib (Votrient, GlaxoSmithKline)
targets VEGFR-1, -2, and -3, PDGFR-a/b, and c-kit,126,127 and
is being evaluated in a phase III study as adjuvant mono-
therapy for patients with stage I NSCLC (NCT00775307). Sor-
afenib (Nexavar, Bayer) is another multitargeted
antiangiogenic TKI that targets both proliferation (raf, c-kit,
and FLT-3) and angiogenesis (VEGFR-2 and -3, PDGFR-b).128
Phase III trials of sorafenib as a component of first-line
chemotherapy for advanced NSCLC (ESCAPE, NCT00300885;
NExUS, NCT00449033; nonsquamous histology only)118,129
both failed to meet their primary endpoints of prolonged
OS; therefore, clinical development of sorafenib for the
treatmentofadvancedNSCLC isexpectedto focuson its useas
monotherapy and in combination with other targeted agents
in the second-line setting and beyond. Sunitinib (Sutent,
Pfizer), an inhibitor of VEGFR-1, -2, and -3, PDGFR-a/b, c-kit,
FLT-3, and RET,130 is currently being evaluated in 2 ongoing
phase III trials in patients with NSCLC in combination with
erlotinib (NCT00457392) and as maintenance therapy (CALGB
30607, NCT00693992).
Table 6 Phase III trials of targeted therapies for NSCLC.a
Agent/trial number Description Primary endpoint
Antiangiogenic agents: small molecule TKIs
BIBF 1120
LUME-Lung 1/
NCT00805194
Placebo-controlled trial in combination with docetaxel
for second-line treatment after failure of a platinum-based
doublet with or without bevacizumab
PFS
LUME-Lung 2/
NCT00806819
Placebo-controlled trial in combination with pemetrexed
for second-line treatment after failure of a platinum-based
doublet with or without bevacizumab
PFS
Cediranib
BR29b/NCT00795340 Placebo-controlled trial in combination with paclitaxel/
carboplatin as first-line therapy
OS
Pazopanib
NCT00775307 Placebo-controlled trial of adjuvant monotherapy
in stage I disease
DFS
Sorafenib
MISSION/NCT00863746 Placebo-controlled trial as third- or fourth-line monotherapy in
patients with tumors of primarily nonsquamous cell histology
OS
Sunitinib
CALGB 30607/
NCT00693992
Placebo-controlled trial as maintenance monotherapy
following first-line chemotherapy
PFS
Other antiangiogenic agents
ASA404
ATTRACT-2c/
NCT00738387
Placebo-controlled trial in combination with docetaxel
as second-line therapy
OS
Agents targeting compensatory EGFR signaling
Crizotinib (PF02341066)
NCT00932893 Open-label trial of monotherapy versus investigator choice of
docetaxel or pemetrexed as second-line therapy after 1 platinum-
based chemotherapy regimen in patients with ALK fusion-positive
disease
PFS
Irreversible multitargeted EGFR TKIs
Afatinib (BIBW 2992)
LUX-Lung 3/
NCT00949650
Open-label trial versus pemetrexed/cisplatin as first-line therapy in
patients with confirmed EGFR mutations
PFS
LUX-Lung 5/
NCT01085136
Open-label trial of afatinib plus weekly paclitaxel versus
investigator’s choice of single-agent chemotherapy following
progression while receiving afatinib monotherapy in NSCLC patients
who failed previous treatment with a reversible EGFR TKI
PFS
LUX-Lung 6/
NCT01121393
Open-label trial versus gemcitabine/cisplatin as first-line
therapy in patients with confirmed EGFR mutations
PFS
PF00299804
BR26/NCT01000025 Placebo-controlled trial of monotherapy in patients who progressed
after standard chemotherapyd and erlotinib or gefitinib
OS
ARCHER1009/
NCT01360554
Placebo-controlled trial of PF00299804 compared with
erlotinib in patients who progressed after 1 or 2 prior
regimens (no prior therapy targeting the HER family)
PFS
Vaccine therapy
NCT01015443 Placebo-controlled trial of Stimuvax
(L-BLP25 or BLP25 liposome vaccine) in Asian patients
with stage III disease with stable disease
or response to primary chemoradiotherapy
OS
(continued on next page)
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Table 6 (continued )
Agent/trial number Description Primary endpoint
NCT00409188 Placebo-controlled trial of Stimuvax
(L-BLP25 or BLP25 liposome vaccine) in patients
with unresectable stage III disease
OS
NCT00516685e Trial of best supportive care versus recombinant
human EGF-rP64K/montanide ISA 51 vaccine
after conventional first-line
chemotherapy
OS
ALK, anaplastic lymphoma kinase; DFS, disease-free survival; EGFR, epidermal growth factor receptor; NSCLC, nonesmall cell lung
cancer; PFS, progression-free survival; OS, overall survival; TKI, tyrosine kinase inhibitor.
a Excluding trials for which follow-up is ongoing but for which efficacy data are available (please see text for studies with results). All
trials are in unresectable advanced/metastatic disease, unless otherwise noted.
b Status listed as closed123; further information is awaited.
c Status listed as “terminated” as of October, 2011.
d 1 to 2 chemotherapy regimens, with a prior combination regimen required for patients age <70 years, but single-agent therapy
permissible for patients age >70 years.
e Status listed as “unknown.”.
486 P. Mazzone, T. MekhailOther antiangiogenic agents
Aside from monoclonal antibodies and TKIs, other types of
antiangiogenic agents are under investigation as NSCLC
therapy. Aflibercept (VEGF Trap) is an antiangiogenic
peptide-antibody fusion comprising portions of VEGFR-1,
VEGFR-2, and immunoglobulin G.131 The addition of afli-
bercept to docetaxel was evaluated as second-line therapy
in a phase III trial of patients with nonsquamous NSCLC
(VITAL).132 The primary endpoint of improved OS was not
reached (10.05 months with aflibercept/docetaxel vs 10.41
months with placebo/docetaxel; HR 1.01; 95.1% CI
0.87e1.17; P Z 0.898) although significant improvements
with aflibercept/docetaxel were reported in PFS (HR 0.82;
95% CI 0.72e0.94; P Z 0.0035) and RR (23.3% vs 8.9%;
P < 0.0001) compared with the placebo arm. Toxicities
observed with at least a 10% higher incidence in the afli-
bercept arm versus placebo included stomatitis, weight
decrease, hypertension, epistaxis and dysphonia.132
Another class of antiangiogenic agents, vascular-
disrupting agents (VDAs), target established vasculature,
in contrast to antiangiogenic agents which inhibit the
development of new blood vessels.133 ASA404 (Novartis) is
a flavanoid small molecule VDA that was evaluated in
a phase III trial in combination with paclitaxel/carboplatin
as first-line therapy for advanced NSCLC (ATTRACT-1;
NCT00662597). This trial was terminated at interim analysis
for futility in prolonging OS134; a second-line phase III study
in combination with docetaxel has also been terminated
secondary to futility (ATTRACT-2; NCT00738387).Agents targeting compensatory EGFR signaling
Figitumumab, a monoclonal antibody directed against IGF-
1R, which shares downstream signaling with EGFR, has also
been evaluated in patients with NSCLC. However, 2 phase III
trials of figitumumab in patients with advanced NSCLC, 1 in
combination with carboplatin/paclitaxel as first-line
therapy135 and another in combination with erlotinib as
second- or third-line therapy,136 were halted due to futility.Other monoclonal antibodies directed against EGFR and
IGF-1R are in earlier stages of clinical development,
including panitumumab137 and AMG 479,138e140 IMC-A12,141
and MK-0646,142,143 respectively.Irreversible multitargeted Next-generation EGFR TKIs
Afatinib (BIBW 2992, Boehringer Ingelheim) is an irrevers-
ible inhibitor of EGFR/HER1, HER2, and HER4.144,145 A phase
IIb/III study (LUX-Lung 1) of afatinib plus usual care versus
placebo plus usual care in patients who progressed after 1
to 2 lines of chemotherapy and 12 weeks of erlotinib or
gefitinib was recently completed.146 Median PFS by inde-
pendent review was 3.3 months for afatinib plus usual care
and 1.1 months for placebo plus usual (HR, 0.38;
P < 0.0001); confirmed disease control rate at 8 weeks was
58% and 19%, respectively (P < 0.0001); and independent
analyses of objective RR was 7.4% and 0.5%, respectively
(P < 0.01). The median OS was not different: 10.8 months
for afatinib plus usual care and 12.0 months for placebo
plus usual care (HR, 1.08; 95% CI, 0.86e1.35).
LUX-Lung 3 (NCT00949650) is a randomized phase III
study of previously untreated EGFR mutation-positive
patients with stage IIIB/IV adenocarcinoma of the lung
who will receive either afatinib or pemetrexed and
cisplatin. LUX-Lung 5 (NCT01085136) is a phase III study in
NSCLC following progression while receiving afatinib mon-
otherapy in patients failing previous treatment with
a reversible EGFR TKI. In this study, patients will be
randomized to receive afatinib and paclitaxel or single-
agent chemotherapy of the investigator’s choice. LUX-
Lung 6 (NCT01121393) is an ongoing study evaluating first-
line afatinib versus gemcitabine and cisplatin in Asian
NSCLC patients with EGFR mutations.
PF00299804 (Pfizer) is an irreversible inhibitor of EGFR/
HER1, HER2, and HER4147 for which preliminary results are
available from studies in various NSCLC treatment settings.
A phase III trial of PF00299804 as monotherapy after
progression during standard chemotherapy is ongoing
(BR26; NCT01000025).
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Pulmonologists play an important role in the evaluation and
management of patients with lung cancer. A basic under-
standing of the medications currently available or in
development, as well as the evidence supporting their use,
allows the pulmonologist to have meaningful conversations
with her or his patients leading up to medical oncology
evaluation. In the appropriate patient population, tradi-
tional chemotherapy has a proven role as adjuvant treat-
ment after curative intent resection, as well as in the
treatment of locally advanced and metastatic disease.
Platinum-based doublet chemotherapy remains the stan-
dard of care for NSCLC. The addition of targeted agents
may be appropriate for selected patients, with a few agents
recently approved for the treatment of NSCLC. Agents
targeting the VEGF pathway (bevacizumab), the EGFR
pathway (erlotinib, gefitinib, cetuximab), or ALK/MET
(crizotinib) have demonstrated efficacy and are recom-
mended as treatment options by the FDA (bevacizumab,
erlotinib, gefitinib, crizotinib) or the NCCN (bevacizumab,
erlotinib, cetuximab, crizotinib) for specific patient pop-
ulations with advanced NSCLC. Recent and ongoing studies
are evaluating novel treatments for NSCLC, such as agents
that target multiple receptors within the VEGF family (eg,
VEGFR-1 and VEGFR-2), multiple angiogenic pathways (eg,
VEGFR and PDGFR pathways), irreversibly inhibit EGFR and
HER2, or target multiple points in the EGFR pathway.
Results from these recently completed and ongoing studies
may have important implications for the future treatment
of patients with NSCLC.
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